MedTrace Logo

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

NCT07346547 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 384

Last updated 2026-01-20

No results posted yet for this study

Summary

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Conditions

  • CKD Anemia

Interventions

DRUG

Daprodustat

Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Sponsors & Collaborators

  • Nabiqasim Industries (Pvt) Ltd

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-30
Primary Completion
2027-01-30
Completion
2027-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07346547 on ClinicalTrials.gov